Ariceum Therapeutics Acquires Theragnostics Ltd.

Lantheus Acquires Life Molecular Imaging from Life Healthcare

July 22, 2025

Healthcare Services

Lantheus Holdings, Inc. completed the acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd., gaining the Neuraceq (florbetaben F18) commercial product, expanded Alzheimer’s radiodiagnostic infrastructure, and additional R&D capabilities. As part of the transaction, Dr. Ludger Dinkelborg (formerly CEO of Life Molecular) will join Lantheus as Head of Research & Development, reporting to the CEO.

ARCHIMED Diagnostics Acquires 60% Stake in ARK Diagnostics

October 28, 2025

Medical Devices

ARCHIMED Diagnostics (ARCHIMED’s diagnostics team) has acquired a 60% stake in Fremont-based ARK Diagnostics from Soulbrain Holdings in a transaction valuing ARK at $428 million. Soulbrain retains and reinvests in a 40% stake and the deal includes a joint-venture agreement to accelerate ARK’s product development and global expansion.

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

Solve Therapeutics Acquires Cereius, a Duke University Spin-Out

June 22, 2023

Biotechnology

Solve Therapeutics, an oncology-focused biopharmaceutical company, has acquired Cereius, a Duke University spin-out that developed a site-specific radiolabeling chemistry platform for targeted radiodiagnostics and radiotherapeutics. The deal transfers Cereius’ platform and team into SolveTx to support development of targeted radionuclide therapeutics and companion diagnostics for oncology; Cereius shareholders will receive an undisclosed upfront payment plus potential milestone and royalty payments.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

AstraZeneca Acquires Neogene Therapeutics

November 29, 2022

Biotechnology

AstraZeneca has agreed to acquire Neogene Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell receptor (TCR) therapies, for up to $320 million. The acquisition strengthens AstraZeneca's oncology cell therapy capabilities by adding Neogene's discovery, development and manufacturing expertise for TCR-Ts targeting solid tumours.